Drug-associated acute kidney injury: who's at risk?

Abstract

The contribution of nephrotoxic medications to the development of acute kidney injury (AKI) is becoming better understood concomitant with the increased incidence of AKI in children. Treatment of AKI is not yet available, so prevention continues to be the most effective approach. There is an opportunity to mitigate severity and prevent the occurrence of AKI if children at increased risk are identified early and nephrotoxins are used judiciously. Early detection of AKI is limited by the dependence of nephrologists on serum creatinine as an indicator. Promising new biomarkers may offer early detection of AKI prior to the rise in serum creatinine. Early detection of evolving AKI is improving and offers opportunities for better management of nephrotoxins. However, the identification of patients at increased risk will remain an important first step, with a focus on the use of biomarker testing and interpretation of the results.

Keywords: Acute kidney injury; Adverse drug reactions; Critical illness; Drug-associated; Drug-related side effects; Nephrotoxic; Pharmacovigilance.

Figure 1

Stage-Based Management of AKI (KDIGO) [9], used with permission. Shading of boxes indicates priority of action; solid shading indicates actions that are equally appropriate at all stages whereas graded shading indicates increasing priority as intensity increases.